Rockwell Medical (RMTI) Getting Somewhat Positive Press Coverage, Report Finds
News headlines about Rockwell Medical (NASDAQ:RMTI) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Rockwell Medical earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news stories about the company an impact score of 48.9332812719799 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news stories that may have effected Accern’s rankings:
- Rockwell Medical : Files Calcitriol Post-Approval Manufacturing Submission with FDA (4-traders.com)
- Comparing TherapeuticsMD (TXMD) & Rockwell Medical (RMTI) (americanbankingnews.com)
- Rockwell Files Calcitriol Post-Approval Manufacturing Submission with FDA (globenewswire.com)
- Rockwell Medical Technologies (RMTI) Says it Filed Calcitriol Post-Approval Manufacturing Submission with FDA (streetinsider.com)
- Financial Survey: Rockwell Medical (RMTI) and Its Rivals (americanbankingnews.com)
RMTI has been the topic of several analyst reports. Zacks Investment Research upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. BidaskClub upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. ValuEngine cut Rockwell Medical from a “hold” rating to a “sell” rating in a report on Friday, June 2nd. Finally, Ifs Securities initiated coverage on Rockwell Medical in a report on Monday, August 14th. They set a “strong-buy” rating and a $11.00 price objective on the stock. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $8.38.
Rockwell Medical (NASDAQ RMTI) traded up 0.47% during midday trading on Friday, hitting $8.56. The stock had a trading volume of 320,834 shares. The firm has a 50 day moving average price of $6.47 and a 200 day moving average price of $7.00. Rockwell Medical has a one year low of $3.55 and a one year high of $8.98. The stock’s market cap is $442.89 million.
Rockwell Medical (NASDAQ:RMTI) last posted its quarterly earnings data on Wednesday, August 9th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.04). Rockwell Medical had a negative return on equity of 42.22% and a negative net margin of 39.68%. The firm had revenue of $13.24 million for the quarter, compared to analysts’ expectations of $13.05 million. During the same quarter in the previous year, the firm posted ($0.11) earnings per share. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. Equities analysts expect that Rockwell Medical will post ($0.44) EPS for the current year.
About Rockwell Medical
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Receive News & Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.